Regression of upper gastric cancer in mice by FHIT gene delivery

被引:47
作者
Ishii, H
Zanesi, N
Vecchione, A
Trapasso, F
Yendamuri, S
Sarti, M
Baffa, R
During, MJ
Huebner, K
Fong, LYY
Croce, CM
机构
[1] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, CNS, Gene Therapy Ctr, Philadelphia, PA 19107 USA
关键词
NMBA; FHIT viruses; forestomach; tumor reversal; Bcl2-Bax;
D O I
10.1096/fj.03-0241fje
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fhit expression is reduced in most cancers, and Fhit replacement by FHIT expression viruses in lung, esophageal, pancreatic, and cervical cancers induces apoptosis in the cancer cells. Mice carrying one or two inactivated Fhit alleles are hypersensitive to development of N-nitrosomethylbenzylamine (NMBA)-induced forestomach tumors. In the present study, we investigated the kinetics and mechanism of tumor reversal and intervention by oral delivery of FHIT expression viruses. Tumor analysis showed that: a) by 37 days post-NMBA, control mice showed similar to7 tumors and by 84 days similar to10 tumors/forestomach; b) mice receiving FHIT virus at 2 or 42 days post-NMBA showed significantly reduced tumor burdens; c) Fhit was still expressed at 82 days postinfection; d) control viral infection had no effect on tumor development; and e) reduced Bcl2, increased Bax expression, and increased TUNEL-positive apoptotic nuclei characterized the restored epithelia of FHIT transduced forestomachs. Thus, FHIT viral gene delivery prevents or retards development of carcinogen-induced forestomach tumors and reverses development of established tumors by 60 - 70% through an apoptotic pathway. This dramatic reduction in tumor burden emphasizes the efficacy of targeting the FHIT apoptotic pathway for tumor eradication.
引用
收藏
页码:1768 / +
页数:15
相关论文
共 16 条
[1]   FHIT gene therapy prevents tumor development in Fhit-deficient mice [J].
Dumon, KR ;
Ishii, H ;
Fong, LYY ;
Zanesi, N ;
Fidanza, V ;
Mancini, R ;
Vecchione, A ;
Baffa, R ;
Trapasso, F ;
During, MJ ;
Huebner, K ;
Croce, CM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (06) :3346-3351
[2]  
Dumon KR, 2001, CANCER RES, V61, P4827
[3]   An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy [J].
During, MJ ;
Symes, CW ;
Lawlor, PA ;
Lin, J ;
Dunning, J ;
Fitzsimons, HL ;
Poulsen, D ;
Leone, P ;
Xu, RA ;
Dicker, BL ;
Lipski, J ;
Young, D .
SCIENCE, 2000, 287 (5457) :1453-1460
[4]   Peroral gene therapy of lactose intolerance using an adeno-associated virus vector [J].
During, MJ ;
Xu, RL ;
Young, D ;
Kaplitt, MG ;
Sherwin, RS ;
Leone, P .
NATURE MEDICINE, 1998, 4 (10) :1131-1135
[5]   Muir-Torre-like syndrome in Fhit-deficient mice [J].
Fong, LYY ;
Fidanza, V ;
Zanesi, N ;
Lock, LF ;
Siracusa, LD ;
Mancini, R ;
Siprashvili, Z ;
Ottey, M ;
Martin, SE ;
Druck, T ;
McCue, PA ;
Croce, CM ;
Huebner, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (09) :4742-4747
[6]   Novel tools for production and purification of recombinant adenoassociated virus vectors [J].
Grimm, D ;
Kern, A ;
Rittner, K ;
Kleinschmidt, JA .
HUMAN GENE THERAPY, 1998, 9 (18) :2745-2760
[7]   FRA3B and other common fragile sites:: The weakest links [J].
Huebner, K ;
Croce, CM .
NATURE REVIEWS CANCER, 2001, 1 (03) :214-221
[8]  
Ishii H, 2001, CANCER RES, V61, P1578
[9]  
Ji L, 1999, CANCER RES, V59, P3333
[10]  
Mori M, 2000, CANCER RES, V60, P1177